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Abstract 
Backgroud 
To describe the use of non-antiretroviral co-medication and combination antiretroviral therapy 
(cART) in HIV/hepatitis C virus (HCV) co-infected patients, and to predict the potential for drug-drug 
interactions (DDIs) with direct-acting antivirals (DAAs) against HCV.  
Methods 
This is a retrospective, cross-sectional study, using the Dutch nationwide ATHENA observational HIV 
cohort database. All patients with a known HIV/HCV co-infection on 1 January 2015 were included. 
Co-medication and cART registered in the database were listed. The potential for DDIs between DAAs 
and co-medication/cART were predicted, using http://hep-druginteractions.org. DDIs were 
categorized as: (1) no clinically relevant DDI; (2) possible DDI; (3) contra-indication; or (4) no 
information available.  
Results 
We included 777 patients of whom 488 (63%) used non-antiretroviral co-medication. At risk for a 
category 2/3 DDI with non-antiretroviral co-medications were 299 patients (38%). Most DDIs were 
predicted with paritaprevir/ritonavir, ombitasvir ± dasabuvir (47% of the drugs) and least with 
grazoprevir/elbasvir (11% of the drugs). 
Concerning cART, daclatasvir/sofosbuvir is the most favourable combination as no cART is contra-
indicated with this combination. In genotype 1/4 patients grazoprevir/elbasvir is least favourable as 
75% of the patients must alter their cART.  
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Conclusions 
This study showed that co-medication use in the aging HIV/HCV population is frequent and diverse. 
There is a high potential for DDIs between DAAs and co-medication/cART.  
 
Keywords: cART, co-medication, direct-acting antivirals, drug–drug interactions, hepatitis C, HIV.  
 
1. Introduction 
Due to shared routes of transmission and overlapping at risk populations, HIV patients are commonly 
co-infected with hepatitis C virus (HCV). It is estimated that, worldwide, 2.3 million people live with 
an HIV/HCV co-infection
1
. In the Netherlands 12% of the HIV-infected patients tested were positive 
for HCV antibody or HCV RNA. The majority of these patients are men who have sex with men (46%) 
or current/former drug users (31%) 
2
.  
Both HIV (combination antiretroviral therapy [cART]) and HCV (direct-acting antivirals [DAAs]) 
treatments can be victims (substrates) and/or perpetrators (cause) of drug–drug interactions (DDIs)
3
. 
For example, nevirapine is a strong inducer of cytochrome P450 (CYP) 3A4, and therefore interacts 
with velpatasvir (CYP3A4 substrate)
4
. On the other hand, the combination of ombitasvir, 
paritaprevir/ritonavir ± dasabuvir (PrO±D), strongly inhibits CYP3A4, causing increased rilpivirine 
(CYP3A4 substrate) levels
5
.  
These examples demonstrate that DDIs could be a potential problem in HIV/HCV co-infected 
patients. So far, this has been studied mainly focusing on cART/DAA interactions
6-9
. However, 
treatment of co-infected patients is complicated in the aging HIV population, as these patients often 
suffer from somatic or psychiatric co-morbidities for which co-medication is prescribed. Thus, 
besides cART, management of DDIs in HIV/HCV co-infected patients should also focus on interactions 
between DAAs and these co-medications. Furthermore, earlier publications in general did not include 
evaluations of the most modern DAAs, such as velpatasvir and grazoprevir/elbasvir, which are now 
recommended first line agents. 
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We aimed to identify the use of co-medication and cART and predicted DDIs of these medications 
with all currently available DAAs in a Dutch nationwide HIV/HCV co-infected cohort.  
2. Methods 
This retrospective, cross-sectional study, used the ATHENA database managed by the HIV monitoring 
Foundation (http://www.hiv-monitoring.nl). This is a Dutch, nationwide registry in which all HIV-
infected patients in care who did not opt-out are registered. All patients with a known HIV/HCV co-
infection on 1 January 2015 were included (HCV RNA positive). These patients were not treated with 
DAAs before, as these drugs became available in the Netherlands on 1 January 2015. The included 
patients represent the total population of patients which could potentially be treated with DAAs and 
co-medication and cART were thus not altered because of DDIs with DAAs. The reported co-
medication and cART was used to predict DDIs using the database of the University of Liverpool 
(http://hep-druginteractions.org; September 2016) 
This analysis was done in four steps: 1) Identification of co-medication used in the cohort; 2) 
prediction of DDIs between co-medication and DAAs; 3) Identification of cART used in the cohort; 4) 
prediction of DDIs between cART and DAAs. 
 
2.1 Identification of co-medication 
All non-antiretroviral co-medication was extracted from the database, from which a list was 
compiled of all unique co-medications.  
 
2.2 Prediction of DDIs between co-medication and DAAs 
The list (2.1) of co-medications was used for the prediction of DDIs. Each drug was cross-checked if 
DDIs exist with one of the DAA-regimens. We included all DAA-regimens recommended in Dutch 
guidelines in November 2016
10
. DDIs were categorized as: (1) no clinically relevant DDI expected; (2) 
possible DDI expected, i.e. monitor the patient or alter drug dosage/timing; (3) contra-indication, do 
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not co-administer; or (4) no information available in the Liverpool database. Category 2 and 3 DDIs 
were defined as clinically relevant.  
We reported per DAA-regimen the number of co-medications with a potential DDI. 
 
After determination of the DDIs between the unique co-medications and DAA-regimens, we assessed 
the number of patients, per genotype, at risk for a clinically relevant DDI. We counted the patients 
that had at least one predicted DDI with any of the DAA-regimens. Dutch recommendations of 
November 2016 were used to determine which DAA-regimen can be used per genotype
10
. Patients 
with an unknown HCV genotype were analyzed with pan-genotypic regimens: sofosbuvir+daclatasvir 
and sofosbuvir+velpatasvir. We reported per genotype, the frequency of patients at risk for a DDI. 
In addition, patients with DDIs were counted for those (a) with or without cirrhosis, and those (b) <60 
or >60 years. Cirrhosis (METAVIR F3/F4) was defined using a pathology or Fibroscan report (stiffness 
>9.5kPa). 
 
2.3 Identification of cART 
Antiretroviral drugs registered in the database were extracted and a list of antiretroviral drugs per 
patient was compiled.  
 
2.4 Prediction of DDIs between cART and DAAs 
The list from 2.3 was used for the prediction of DDIs. To simplify the analysis only patients with a 
double nucleoside reverse transcriptase inhibitors (NRTI) backbone and 1 additional drug were 
included. These additional drugs can be a (boosted) protease inhibitor (PI), (boosted) integrase 
inhibitor (INSTI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). These additional drugs 
are usually causing DDIs and therefore used in this analysis. Patients with other regimens were 
excluded. Per genotype and DAA-regimen the number of patients at risk for a DDI was reported. 
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Lastly, the patients using tenofovir disoproxil fumarate (TDF) and boosted PIs were identified. This 
combination interacts with ledipasvir and velpatasvir causing possible renal toxicity. It is therefore 
recommended to discontinue TDF or the boosted PI prior to ledipasvir and velpatasvir therapy 
(category 2).  
Analyses were performed using IBM SPSS Statistics 20. 
3. Results 
The ATHENA database contained data on 777 HIV/HCV co-infected patients known to be in care on 1 
January 2015. The majority of these patients were male (666; 86%). The median (range) age was 49.3 
(23-80) years; 689 patients were <60 years and 88 were ≥60 years. METAVIR score F0/F1/F2 was 
reported for 438 (56%) patients and F3/F4 for 181 (23%) patients (158 unknown). Genotype 1 and 4 
were most prevalent, in 495 (64%) and 139 (18%) patients, respectively (supplementary Table 1 
http://links.lww.com/QAI/B59). 
 
3.1 Identification of co-medication  
An overview of co-medication use is presented in Figure 1, showing that 488 patients used 156 
unique non-antiretroviral co-medications. Medication use varied from 1 to 14 prescriptions per 
patient (excluding cART), in total 1,245 prescriptions were reported. Most frequently used 
medications were drugs for opioid dependence (138; 11%), proton pump inhibitors (110; 9%), 
calcium supplements (77; 6%), selective serotonin reuptake inhibitors (56; 4%), platelet aggregation 
inhibitors (53; 4%), Vitamin D (46; 4%), and statins (45; 4%). In Supplementary table 2 
http://links.lww.com/QAI/B59 these drug classes are broken down to the drugs that were prescribed  
at least to 10 patients (single molecules). 
 
3.2 Prediction of DDIs between co-medications and DAAs  
Grazoprevir/elbasvir and sofosbuvir/velpatasvir had the lowest number of predicted DDIs with the 
156 co-medications. PrO±D and sofosbuvir/simeprevir account for the highest number of predicted 
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category 2 and 3 interactions with the used co-medication. Overall, the number of truly contra-
indicated drugs is low, with a maximum of 10 drugs for PrO±D. We were not able to predict potential 
DDIs of 23 drugs (category 4), as these drugs were unavailable in the Liverpool database (Figure 1). 
Converting the number of drugs (156) to the number of patients with a category 2 or 3 DDI with any 
of the DAAs, we found that 299 patients were at risk. This concerns 205 (41%) genotype 1, 34 (36%) 
genotype 2/3, 54 (39%) genotype 4, and 6 (12%) patients with an unknown genotype. Furthermore, 
269 (40%) patients <60 years and 55 (77%) patients ≥60 years were at risk for a category 2 or 3 DDI 
with any of the DAA-regimens. Similarly, 147 (34%) and 100 (55%) patients without and with 
cirrhosis, respectively, were at risk for a DDI.  
 
3.3 Identification of cART 
A total of 762 (98%) patients were treated with cART. The NRTI backbone containing 
TDF+emtricitabine was used by 536 (70%) of patients and 103 (14%) patients used 
abacavir+lamivudine.  
The majority of patients used 1 additional (e.g. PI, INSTI, NNRTI) antiretroviral drug (670; 88%) and 40 
(5%) patients used more than 1 additional antiretroviral. Most frequently used additional drugs were 
NNRTIs (307; 46%), followed by the boosted PIs (247; 37%), and INSTIs (116; 17%). Please note that 
on the date of evaluation, 1 January 2015, dolutegravir had only been available for 2 months. 
 
3.4 Prediction of DDIs between cART and DAAs 
Per genotype, the predicted DDIs per patients are shown (n = 669; Figure 2). None of the genotype 1 
and 4 patients would have to change their cART when treated with sofosbuvir/daclatasvir. However, 
the dosage of daclatasvir should be altered depending on some specific cART regimens. Ledipasvir 
and velpatasvir in combination with sofosbuvir can be safely used with all third additional drugs. 
However, 199 (31%) genotype 1 or 4 patients used TDF with boosted PIs, which makes it necessary to 
switch either TDF or the PI. Comparable, in combination with velpatasvir patients infected with all 
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genotypes using TDF with a boosted PI (n = 231; 29%), are recommended to switch either TDF or the 
PI. 
Grazoprevir/elbasvir causes the most category 3 DDIs, making a change in DAA or cART regimen 
necessary. Other regimens with category 3 interactions were sofosbuvir with velpatasvir/simeprevir 
and PrO±D. For patients with genotype 2/3 or an unknown genotype it is shown that 
sofosbuvir/daclatasvir can be used without cART switch.   
 
4. Discussion 
This cohort represents all Dutch HIV/HCV co-infected patients in care in the Netherlands who might 
be treated with the novel DAAs. Most commonly used co-medications reflect the characteristics of 
the HIV/HCV patient population, such as the drugs used for opioid dependence
2
. Other drug classes 
in the top 5 are comparable with HCV mono-infected patients in The Netherlands
11
 and represent the 
aging HIV population with an increasing number of co-morbidities. This is supported by our subgroup 
analysis where patients ≥60 years had a higher risk of DDIs than patients <60 years. Similarly, 
patients with cirrhosis had a higher predicted risk of DDIs than patients without cirrhosis. This is 
comparable with findings in HCV mono-infected patients
12
.  
PrO±D and sofosbuvir/simeprevir have the highest number of predicted DDIs with non-antiretroviral 
co-medication, which is in line with previous studies
6,8,9
. Both combinations contain inhibitors of 
CYP3A4 (i.e. ritonavir, simeprevir), which is the main drug-metabolizing enzyme
5,13
. However, we 
must mention that in daily practice these regimens are infrequently used, because of the e.g. the 
DDIs and protease inhibitor related side effects. 
Grazoprevir/elbasvir had the lowest number of DDIs with co-medication, because they have minimal 
influence on drug-enzymes and transporters
14
. One should notice that grazoprevir is a mild inhibitor 
of CYP3A4. Therefore, we recommend being careful with CYP3A4 substrates with a narrow 
therapeutic range. However, it remains unclear whether these DDIs are clinically relevant.  
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Sofosbuvir/daclatasvir can be easily combined with cART, because of the possibility of a dose 
adaptation and no contra-indicated cART regimens. Despite the fact that ledipasvir has only category 
2 DDIs, it is less favourable, because ledipasvir is not recommended with the combination of a 
boosted PI and TDF, an issue that would require a switch in cART in 31% of patients. This interaction, 
as well as the interaction with velpatasvir (29%), can also be avoided when switching from TDF to 
tenofovir alafenamide (TAF). TAF plasma concentrations are not affected by ledipasvir
15
.  
In most countries, the separate agents daclatasvir and sofosbuvir are in general a more expensive 
DAA-regimen compared with the fixed-dose combinations with velpatasvir and ledipasvir and 
therefore prescribed in a lesser extent. In the Netherlands, the prices of DAAs are unknown and 
therefore not a criteria for selecting a DAA-regimen 
10
. 
It is striking that grazoprevir/elbasvir has the lowest number of interactions with non-antiretroviral 
co-medication, but this combination has the highest number of DDIs with cART. Grazoprevir/elbasvir 
(and simeprevir) is contra-indicated with all boosted PIs, NNRTIs (except rilpivirine) and 
elvitegravir/cobicistat; this makes it an unfavourable combination in this co-infected population 
because almost all patients would need to alter their cART regimen, if they are not already on 
raltegravir or dolutegravir. NNRTIs and PIs are most frequently used in our cohort, but with the 
introduction of dolutegravir, the use of NNRTIs and PIs decreased
2
.  
A limitation of the analysis is that patients with the most complicated cART regimens (e.g. >1 
additional drug, no NNRTI backbone) were excluded from the analysis presented in Figure 2. These 
patients are probably the most difficult to treat HIV patients, because they have deviating cART 
regimens, and therefore, switching cART is probably not an option in these cases (e.g. resistance, 
toxicity). For these patients, the treatment strategy is to use a DAA-regimen with least number of 
(possible) drug-interactions. 
Lastly, we must comment that the majority of the DDIs which are discussed in this paper are only 
studied in healthy volunteers and not in HIV/HCV co-infected patients. These drug interactions 
studies in healthy volunteers give a good indication of the direction of the DDI, however, as healthy 
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volunteers substantially differ from HIV/HCV co-infected the magnitude of the DDIs could differ as, 
for example, the exposure to DAAs and antiretroviral drugs is probably different in healthy 
volunteers and HIV/HCV patients
16
. 
Concluding, this study showed that co-medication use in the aging HIV/HCV population is frequent 
and diverse and that there is a high potential of DDIs between DAAs plus co-medication/cART. 
Combining the results from our analysis, from the perspective of potential DDIs with co-medication 
and/or cART, the most favourable regimen seems to be  sofosbuvir/daclatasvir.  
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CLINICAL CENTRES 
* denotes site coordinating physician 
Academic Medical Center of the University of Amsterdam: HIV treating physicians: J.M. Prins*, T.W. 
Kuijpers, H.J. Scherpbier, J.T.M. van der Meer, F.W.M.N. Wit, M.H. Godfried, P. Reiss, T. van der Poll, 
F.J.B. Nellen, S.E. Geerlings, M. van Vugt, D. Pajkrt, W.J. Wiersinga, M. van der Valk, A. Goorhuis, J.W. 
Hovius. HIV nurse consultants: M.A.H. Bijsterveld, J. van Eden, A.M.H. van Hes, M. Mutschelknauss, 
H.E. Nobel, F.J.J. Pijnappel,  A.M. Weijsenfeld. HIV clinical virologists/chemists: S. Jurriaans, N.K.T. 
Back, H.L. Zaaijer, B. Berkhout, M.T.E. Cornelissen, C.J. Schinkel, X.V. Thomas. Admiraal De Ruyter 
Ziekenhuis, Goes: HIV treating physicians: M. van den Berge, A. Stegeman. HIV nurse consultants: S. 
Baas, L. Hage de Looff. HIV clinical virologists/chemists: B Wintermans, J Veenemans. Catharina 
Ziekenhuis, Eindhoven: HIV treating physicians: M.J.H. Pronk*, H.S.M. Ammerlaan. HIV nurse 
consultants: E.S. de Munnik, E. van Beek. HIV clinical virologists/chemists: A.R. Jansz, J. Tjhie, M.C.A. 
Wegdam, B. Deiman, V. Scharnhorst. Elisabeth-TweeSteden Ziekenhuis, Tilburg: HIV treating 
physicians: M.E.E. van Kasteren*, A.E. Brouwer. HIV nurse consultants: R. van Erve, B.A.F.M. de Kruijf-
van de Wiel, S.Keelan-Pfaf, B. van der Ven. Data collection: B.A.F.M. de Kruijf-van de Wiel, B. van der 
Ven.  HIV clinical virologists/chemists: A.G.M. Buiting, P.J. Kabel, D.Versteeg. Emma 
Kinderziekenhuis, Amsterdam: HIV nurse consultants: A. van der Plas, A.M. Weijsenfeld. Erasmus 
MC, Rotterdam: HIV treating physicians: M.E. van der Ende*, H.I. Bax, E.C.M. van Gorp, J.L. Nouwen, 
B.J.A. Rijnders, C.A.M. Schurink, A. Verbon, T.E.M.S. de Vries-Sluijs. HIV nurse consultants: N. Bassant, 
J.E.A. van Beek, M. Vriesde, L.M. van Zonneveld. Data collection: H.J. van den Berg-Cameron, F.B. 
Bruinsma-Broekman, J. de Groot, M. de Zeeuw-de Man. HIV clinical virologists/chemists: C.A.B. 
Boucher, M.P.G Koopmans, J.J.A van Kampen, S.D. Pas. Erasmus MC–Sophia, Rotterdam: HIV 
treating physicians: G.J.A. Driessen, A.M.C. van Rossum. HIV nurse consultants: L.C. van der Knaap, E. 
Visser. Flevoziekenhuis, Almere: HIV treating physicians: J. Branger*, A. Rijkeboer-Mes. HIV nurse 
consultant and data collection: C.J.H.M. Duijf-van de Ven. HagaZiekenhuis, Den Haag: HIV treating 
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physicians: E.F. Schippers*, C. van Nieuwkoop. HIV nurse consultants: J.M. van IJperen, J. Geilings. 
Data collection: G. van der Hut. HIV clinical virologist/chemist: P.F.H. Franck. HIV Focus Centrum (DC 
Klinieken), Amsterdam: HIV treating physicians: A. van Eeden*. HIV nurse consultants: W. Brokking, 
M. Groot, L.J.M. Elsenburg. HIV clinical virologists/chemists: M. Damen, I.S. Kwa. Isala, Zwolle: HIV 
treating physicians: P.H.P. Groeneveld*, J.W. Bouwhuis. HIV nurse consultants: J.F. van den Berg, 
A.G.W. van Hulzen. Data collection: G.L. van der Bliek, P.C.J. Bor. HIV clinical virologists/chemists: P. 
Bloembergen, M.J.H.M. Wolfhagen, G.J.H.M. Ruijs. Leids Universitair Medisch Centrum, Leiden: HIV 
treating physicians: F.P. Kroon*, M.G.J. de Boer, H. Jolink, A.M. Vollaard. HIV nurse consultants: W. 
Dorama, N. van Holten. HIV clinical virologists/chemists: E.C.J. Claas, E. Wessels. Maasstad 
Ziekenhuis, Rotterdam: HIV treating physicians: J.G. den Hollander*, K. Pogany, A. Roukens. HIV 
nurse consultants: M. Kastelijns, J.V. Smit, E. Smit, D. Struik-Kalkman, C. Tearno. Data collection: M. 
Bezemer, T. van Niekerk. HIV clinical virologists/chemists: O. Pontesilli. Maastricht UMC+, 
Maastricht: HIV treating physicians: S.H. Lowe*, A.M.L. Oude Lashof, D. Posthouwer. HIV nurse 
consultants: R.P. Ackens, J. Schippers, R. Vergoossen. Data collection: B. Weijenberg-Maes. HIV 
clinical virologists/chemists: I.H.M. van Loo, T.R.A. Havenith. MCH-Bronovo, Den Haag: HIV treating 
physicians: E.M.S. Leyten*, L.B.S. Gelinck. HIV nurse consultants: A.Y. van Hartingsveld, C. Meerkerk, 
G.S. Wildenbeest. HIV clinical virologists/chemists: J.A.E.M. Mutsaers, S.Q. van Veen. MC Slotervaart, 
Amsterdam: HIV treating physicians: J.W. Mulder*, S.M.E. Vrouenraets, F.N. Lauw. HIV nurse 
consultants: M.C. van Broekhuizen, H. Paap, D.J. Vlasblom. HIV clinical virologists/chemists: P.H.M. 
Smits. MC Zuiderzee, Lelystad: HIV treating physicians: S. Weijer*, R. El Moussaoui. HIV nurse 
consultant: A.S. Bosma. Medisch Centrum Leeuwarden, Leeuwarden: HIV treating physicians: 
M.G.A.van Vonderen*, D.P.F. van Houte, L.M. Kampschreur. HIV nurse consultants: K. Dijkstra, S. 
Faber. HIV clinical virologists/chemists: J Weel. Medisch Spectrum Twente, Enschede: HIV treating 
physicians: G.J. Kootstra*, C.E. Delsing. HIV nurse consultants: M. van der Burg-van de Plas, H. Heins. 
Data collection: E. Lucas. Noordwest Ziekenhuisgroep, Alkmaar: HIV treating physicians: W. 
Kortmann*, G. van Twillert*, J.W.T. Cohen Stuart, B.M.W. Diederen, R. Renckens. HIV nurse 
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consultant and data collection: D. Ruiter-Pronk, F.A. van Truijen-Oud. HIV clinical 
virologists/chemists: W. A. van der Reijden, R. Jansen. OLVG, Amsterdam: HIV treating physicians: K. 
Brinkman*, G.E.L. van den Berk, W.L. Blok, P.H.J. Frissen, K.D. Lettinga W.E.M. Schouten, J. Veenstra. 
HIV nurse consultants: C.J. Brouwer, G.F. Geerders, K. Hoeksema, M.J. Kleene, I.B. van der Meché, M. 
Spelbrink, H. Sulman, A.J.M. Toonen, S. Wijnands. HIV clinical virologists: M. Damen, D. Kwa. Data 
collection: E. Witte. Radboudumc, Nijmegen: HIV treating physicians: R. van Crevel*, M. Keuter, 
A.J.A.M. van der Ven, H.J.M. ter Hofstede, A.S.M. Dofferhoff. HIV nurse consultants: M. Albers, K.J.T. 
Grintjes-Huisman, M. Marneef, A. Hairwassers. HIV clinical virologists/chemists: J. Rahamat-
Langendoen. HIV clinical pharmacology consultant: D. Burger. Rijnstate, Arnhem: HIV treating 
physicians: E.H. Gisolf*, R.J. Hassing, M. Claassen. HIV nurse consultants: G. ter Beest, P.H.M. van 
Bentum, N. Langebeek. HIV clinical virologists/chemists: R. Tiemessen, C.M.A. Swanink. Spaarne 
Gasthuis, Haarlem: HIV treating physicians: S.F.L. van Lelyveld*, R. Soetekouw. HIV nurse 
consultants: L.M.M. van der Prijt, J. van der Swaluw. Data collection: N. Bermon. HIV clinical 
virologists/chemists: W.A. van der Reijden, R. Jansen, B.L. Herpers, D.Veenendaal. Medisch Centrum 
Jan van Goyen, Amsterdam: HIV treating physicians: D.W.M. Verhagen. HIV nurse consultants: M. 
van Wijk. Universitair Medisch Centrum Groningen, Groningen: HIV treating physicians: W.F.W. 
Bierman*, M. Bakker, J. Kleinnijenhuis, E. Kloeze, H. Scholvinck, Y. Stienstra, C.L. Vermont, K.R. 
Wilting. HIV nurse consultants: A. Boonstra, H. de Groot-de Jonge, P.A. van der Meulen, D.A. de 
Weerd. HIV clinical virologists/chemists: H.G.M. Niesters, C.C. van Leer-Buter, M. Knoester. 
Universitair Medisch Centrum Utrecht, Utrecht: HIV treating physicians: A.I.M. Hoepelman*, J.E. 
Arends, R.E. Barth, A.H.W. Bruns, P.M. Ellerbroek, T. Mudrikova, J.J. Oosterheert, E.M. Schadd, 
M.W.M. Wassenberg, M.A.D. van Zoelen. HIV nurse consultants: K. Aarsman, D.H.M. van Elst-
Laurijssen, E.E.B. van Oers-Hazelzet. Data collection: M. van Berkel. HIV clinical virologists/chemists: 
R. Schuurman, F. Verduyn-Lunel, A.M.J. Wensing. VUmc, Amsterdam: HIV treating physicians: E.J.G. 
Peters*, M.A. van Agtmael, M. Bomers, J. de Vocht. HIV nurse consultants: M. Heitmuller, L.M. Laan. 
HIV clinical virologists/chemists: C.W. Ang, R. van Houdt, A.M. Pettersson, C.M.J.E. Vandenbroucke-
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Grauls. Wilhelmina Kinderziekenhuis, UMCU, Utrecht: HIV treating physicians: S.P.M. Geelen, T.F.W. 
Wolfs, L.J. Bont. HIV nurse consultants: N. Nauta.  
 
 
COORDINATING CENTRE  
Director: P. Reiss. Data analysis: D.O. Bezemer, A.I. van Sighem, C. Smit, F.W.M.N. Wit, T.S. Boender. 
Data management and quality control: S. Zaheri, M. Hillebregt, A. de Jong. Data monitoring: D. 
Bergsma, A. de Lang, S. Grivell, A. Jansen, M.J. Rademaker, M. Raethke, R. Meijering, S. Schnörr. Data 
collection: L. de Groot, M. van den Akker, Y. Bakker, E. Claessen, A. El Berkaoui, J. Koops, E. Kruijne, C. 
Lodewijk, L. Munjishvili, B. Peeck, C. Ree, R. Regtop, Y. Ruijs, T. Rutkens, L. van de Sande, M. Schoorl, 
A. Timmerman, E. Tuijn, L. Veenenberg, S. van der Vliet, A. Wisse, T. Woudstra. Patient registration: 
B. Tuk. 
 
 
Figure 1: Flow chart of the study including the number of predicted drug-drug interactions with 
various DAA-regimens and co-medication. A total of 1,245 prescriptions were available for 488 
patients. These prescriptions contained 156 unique drugs, which were used for the analysis. 
 
The number of drugs for each category are shown in parentheses. Category 1, 2, 3 and 4, 
respectively. 
DDI, drug–drug interaction; HCV, hepatitis C virus; PrOD, ombitasvir, paritaprevir, ritonavir with 
dasabuvir; PrO, ombitasvir, paritaprevir, ritonavir; SOF + SIM, sofosbuvir and simeprevir; SOF + LED, 
sofosbuvir and ledipasvir; SOF + DAC, sofosbuvir and daclatasvir; SOF + VEL, sofosbuvir and 
velpatasvir, GRV + EBV: grazoprevir and elbasvir. 
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Figure 2: The number of patients predicted to have a drug interaction between cART and the 
various combinations of direct-acting antivirals shown per genotype.  
 
Only patients with one additional (third) drug are included in this analysis (n=670).  
Genotype 6 is excluded from this analysis, as only one patient was listed with genotype 6 (n=669). 
Category 2 30 mg: reduce the daclatasvir dose to 30 mg. 
Category 2 90 mg: increase the daclatasvir dose to 90 mg. 
PrOD, ombitasvir, paritaprevir, ritonavir with dasabuvir; PrO, ombitasvir, paritaprevir, ritonavir; SOF + 
SIM, sofosbuvir and simeprevir; SOF + LED, sofosbuvir and ledipasvir; SOF + DAC, sofosbuvir and 
daclatasvir; SOF + VEL, sofosbuvir and velpatasvir; GRV + EBV, grazoprevir and elbasvir. 
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